Peptide T1249

Peptide T1249 Uses, Dosage, Side Effects, Food Interaction and all others data.

Peptide T1249 is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast track designation from the FDA and is in Phase I/II clinical testing.

Table Of contents

• Peptide T1249
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Peptide T1249
Generic	Tifuvirtide
Tifuvirtide Other Names	Peptide T1249, Tifuvirtide
Type
Formula	C235H341N57O67
Weight	Average: 5036.5637 Monoisotopic: 5033.502833871
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections and HIV infection.

How Peptide T1249 works

Peptide T1249 binds to a slightly different region of the HIV virus than Fuzeon (enfuvirtide). As a result,it exhibits activity against Fuzeon-resistant viruses. Peptide T1249 is designed to block fusion of HIV with host cells before the virus enters the cell and begins its replication process.

Innovators Monograph

You find simplified version here Peptide T1249